Trial reportDiabetes care2023
Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial.
Trial report in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.Diabetes, obesity & metabolism · 2026Pooled it
- The Impact of Hypoglycaemia on Quality of Life in Adults With Type 1 Diabetes Using Contemporary Diabetes Technologies: A US National Survey.Diabetes, obesity & metabolism · 2026Article
- Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care.Journal of diabetes science and technology · 2026Article
- Effects of automated insulin delivery systems on glucose control in subgroups of adults with type 1 diabetes in clinical practice over 2 years in Sweden.Scientific reports · 2026Article
- Technology readiness associated with insulin pump and automated insulin delivery system use in young adults with type 1 diabetes.Journal of health psychology · 2026Article
- When Type 2 Diabetes Isn't Type 2: Latent Autoimmune Diabetes in a Lean, Highly Physically Active Adult.Cureus · 2026Article
- Hypoglycemia incidence and behavioural adjustments during free-living unstructured physical activity in adults with type 1 diabetes using AID systems: Results from the RAPPID study.Diabetes, obesity & metabolism · 2025Observational
- Tubeless Insulin Pump Combined with a Cloud-Based Data Management Platform: Real-World Evidence from 14,765 French People with Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Assessment of the added value of a tubeless pump: A time trade-off (TTO) study for utility elicitation of insulin delivery systems in type 1 diabetes mellitus (T1D).Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Evaluation of Glycemia Risk Index and Continuous Glucose Monitoring Outcomes Following the Transition to an Advanced Hybrid Closed-Loop System in Type 1 Diabetes.Advances in therapy · 2025Article
- Effectiveness of continuous glucose monitoring systems on glycemic control in adults with type 1 diabetes: A systematic review and meta-analysis.Metabolism open · 2025Article
- Daytime and nighttime glycemic control with control-IQ technology vs. standard therapy in type 1 diabetes: a systematic review and meta-analysis with trial sequential analysis and GRADE assessment.Diabetology & metabolic syndrome · 2025Review
- Artificial Pancreas: The First 20 Years.Journal of diabetes science and technology · 2025Article
- Impact of Islet Transplantation on Diabetes Complications and Mortality in Patients Living With Type 1 Diabetes.Diabetes care · 2025Article
- Observational
- Efficacy of automated insulin delivery systems in people with type 1 diabetes: a systematic review and network meta-analysis of outpatient randomised controlled trials.EClinicalMedicine · 2025Article
- Effectiveness of open-source Android artificial pancreas systems for glucose management in patients with type 1 diabetes: a real-world study.Therapeutic advances in endocrinology and metabolism · 2025Article
- One-year evaluation of automated insulin delivery systems in adults with type 1 diabetes.Frontiers in digital health · 2025Article
- The impact of technology on impaired awareness of hypoglycaemia in type 1 diabetes.Therapeutic advances in endocrinology and metabolism · 2025Review
- Automated Insulin Delivery for Type 1 Diabetes: Present and Future.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveAssess the safety and efficacy of automated insulin delivery (AID) in adults with type 1 diabetes (T1D) at high risk for hypoglycemia. RESEARCH DESIGN AND
methodsParticipants were 72 adults with T1D who used an insulin pump with Clarke Hypoglycemia Perception Awareness scale score >3 and/or had severe hypoglycemia during the previous 6 months confirmed by time below range (TBR; defined as sensor glucose [SG] reading <70 mg/dL) of at least 5% during 2 weeks of blinded continuous glucose monitoring (CGM). Parallel-arm, randomized trial (2:1) of AID (Tandem t:slim ×2 with Control-IQ technology) versus CGM and pump therapy for 12 weeks. The primary outcome was TBR change from baseline. Secondary outcomes included time in target range (TIR; 70-180 mg/dL), time above range (TAR), mean SG reading, and time with glucose level <54 mg/dL. An optional 12-week extension with AID was offered to all participants.
resultsCompared with the sensor and pump (S&P), AID resulted in significant reduction of TBR by -3.7% (95% CI -4.8, -2.6), P < 0.001; an 8.6% increase in TIR (95% CI 5.2, 12.1), P < 0.001; and a -5.3% decrease in TAR (95% CI -87.7, -1.8), P = 0.004. Mean SG reading remained similar in the AID and S&P groups. During the 12-week extension, the effects of AID were sustained in the AID group and reproduced in the S&P group. Two severe hypoglycemic episodes occurred using AID.
conclusionsIn adults with T1D at high risk for hypoglycemia, AID reduced the risk for hypoglycemia more than twofold, as quantified by TBR, while improving TIR and reducing hyperglycemia. Hence, AID is strongly recommended for this specific population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.